pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
endoxan for injection 1 gvial
baxter healthcare (asia) pte ltd - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous - injection, powder, for solution - 1 g/vial - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous 1 g/vial
endoxan for injection 200 mgvial
baxter healthcare (asia) pte ltd - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous - injection, powder, for solution - 200 mg/vial - cyclophosphamide monohydrate eqv cyclophosphamide anhydrous 200 mg/vial
endoxan for injection 500 mgvial
baxter healthcare (asia) pte ltd - cyclophosphamide anhydrous - injection, powder, for solution - 500 mg/vial - cyclophosphamide anhydrous 500 mg/vial
holoxan for injection 1 g25 ml
baxter healthcare (asia) pte ltd - ifosfamide - injection, powder, for solution - 1 g/25 ml - ifosfamide 1 g/25 ml
mitoxantrone baxter solution for injection 20mg10ml (2mgml)
baxter healthcare (malaysia) sdn. bhd. - mitoxantrone hydrochloride -
baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag
baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.
baxter potassium chloride 10 mmol and 0.29% sodium chloride 100 ml intravenous infusion bag
baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.
baxter potassium chloride 30 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag
baxter healthcare pty ltd - potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.
baxter potassium chloride 20 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag
baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.